Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1977 1
1982 1
1987 1
1988 1
1989 2
1990 1
1992 2
1993 1
1996 2
1997 1
1998 3
1999 3
2000 1
2001 1
2003 5
2004 8
2005 7
2006 6
2007 10
2008 15
2009 8
2010 14
2011 9
2012 17
2013 12
2014 16
2015 17
2016 23
2017 26
2018 26
2019 27
2020 17
2021 30
2022 33
2023 37
2024 29
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for peres, l
Search for Peresh L instead (1 results)
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Hansen DK, et al. Among authors: peres lc. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623248 Free PMC article.
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: peres lc. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. Among authors: peres lc. J Clin Oncol. 2025 May;43(13):1597-1609. doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18. J Clin Oncol. 2025. PMID: 39965175
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: peres lc. Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945. Blood. 2025. PMID: 39365257
Capsaicinoids: Pungency beyond Capsicum.
Naves ER, de Ávila Silva L, Sulpice R, Araújo WL, Nunes-Nesi A, Peres LEP, Zsögön A. Naves ER, et al. Among authors: peres lep. Trends Plant Sci. 2019 Feb;24(2):109-120. doi: 10.1016/j.tplants.2018.11.001. Epub 2019 Jan 7. Trends Plant Sci. 2019. PMID: 30630668 Review.
Renal liposarcoma.
Bader DA, Peres LA, Bader SL. Bader DA, et al. Among authors: peres la. Int Braz J Urol. 2004 May-Jun;30(3):214-5. doi: 10.1590/s1677-55382004000300007. Int Braz J Urol. 2004. PMID: 15689251 Free article.
Prevention of Epithelial Ovarian Cancer.
Sellers TA, Peres LC, Hathaway CA, Tworoger SS. Sellers TA, et al. Among authors: peres lc. Cold Spring Harb Perspect Med. 2023 Aug 1;13(8):a038216. doi: 10.1101/cshperspect.a038216. Cold Spring Harb Perspect Med. 2023. PMID: 37137500 Free PMC article. Review.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Bhurtel E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G. Banerjee R, et al. Among authors: peres lc. Blood Adv. 2025 May 13;9(9):2336-2340. doi: 10.1182/bloodadvances.2025016131. Blood Adv. 2025. PMID: 40088469 Free PMC article. No abstract available.
Why Should Clinical Autopsies Continue to Exist?
Ramos SG, Ottaviani G, Peres LC, Rattis BAC, Leão PS, Akel TN, Ussem L, Prado CAC, Moises ECD, Grimm LCA, Dias EP. Ramos SG, et al. Among authors: peres lc. Diagnostics (Basel). 2021 Aug 16;11(8):1482. doi: 10.3390/diagnostics11081482. Diagnostics (Basel). 2021. PMID: 34441416 Free PMC article.
399 results